TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: dermal safety outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to first occurrence of ischemia-driven revascularization or hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Drug toxicity (grade 3 & 4 DAD Scale)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Markedly Abnormal Value (MAV) Criteria for Safety Laboratory Tests At Least Once Post-dose
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of ARQ 197
Endpoint domain: Adverse events/effects
Primary endpoint: Local regional progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Total recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Positive Anti-Drug Antibodies (ADA)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Clinically Significant Laboratory Abnormality
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Bladder Volume at First Detrusor Contraction at 6 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Average Number of Daily Micturitions at 6 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sensory evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive development composite score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Gastric Outlet Obstruction Scoring System (GOOSS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Placental vascular pathology
Endpoint domain: Adverse events/effects
Primary endpoint: Pregnancy pathology requiring hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Complications from antithrombotic treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Shear-induced platelet activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Faces Pain Scale (FPS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial Affective Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of intestinal parasitic infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: haemorrhagic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of tailored RTX infusions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in active control zone of the elbow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in esthetic patient satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median VAS Improvement Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDRS-17 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total heparin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in lateral hip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain with single leg step down
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain with double leg squat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain with drop jump from 2 foot platform
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss in kg/m²
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of endocannabinoids and corticoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bilateral Bispectral Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: E/SRE ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with placenta accreta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of patients with bladder injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patients with intestinal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patients with cesarean hysterectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in marginal bone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRT response assessed by echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: proSPI (s) at Week 16 Compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of saSPI (s) at Week 16 Compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of dually diagnosed participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anxiety or depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Objective Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of score on Parkinson's Disease Questionnaire 39 (PDQ 39)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in the Microdialysis Cortisone Challenge (MCC) Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in the Oral Cortisone Challenge (OCC) Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Concentration of the glyco-metabolic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Therapeutic adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Long-term diabetes complications
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance to the PECARN CT Scan Head Injury rules
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of bleeding after EMR
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of M. tuberculosis and resistant-conferring mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: First occurrence of HF-related healthcare resource utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Subjects With Severe Rotavirus Gastroenteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent Change in Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Incontinence Episodes Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) of OCA and conjugates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration versus time curve (AUCt) of OCA and conjugates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cmax (Tmax) of OCA and conjugates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number Of Participants With Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number Of Participants With Dose-limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Hazard ratios for all-site and site specific cancer
Endpoint domain: Mortality/survival
Primary endpoint: Mean Change in Nighttime Symptoms Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease confirmation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIH Chronic Prostatitis Symptom Index (NIH-CPSI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: the primary outcome
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: State-Trait Anxiety Inventory Y (STAI-Y) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of renal dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean Change in Cisternal Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Detection of pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline SWAL-QOL survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hospitalizations related to heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of response and stable disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet response in Chronic ITP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete Response in platelet response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Engraftment syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Remission rate of Graves' disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MGMT promoter methylation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Annualized rate of moderate or severe COPD exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Best objective response rate (Complete Response + Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with non-progressive local disease at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uterine incision closure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Antibody response to vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Recession Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Glycosylated Hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in patient reported outcome measures scores (PROMs)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Asthma control status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intrahepatic cccDNA reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With PSA Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Endothelial reactivity (PAT-RH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Circulating DNA Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PWA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Socialization Subscale Scores of the Vineland Adaptive Behavior Scales (VABS-II)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Emotion Guessing Game (EGG) Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: ANI variation after stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of an HIV Test at Study Completion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Number of Condomless Anal Sex Acts at 4 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects electing ovarian tissue cryopreservation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical response by ECCA scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in hepatic steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Inflammatory Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in glycemic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Myocardial uptake of 68Ga-NODAGA-RGD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Barratt Impulsiveness Scale (BIS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Receipt of MOM at NICU Discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Reporting one or More Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Child adaptive functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean percent change in countable convulsive seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: SARS-CoV-2 IgG antibody level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in EPA+DHA-derived lipid mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in reduction in wound area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Documentation of Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Berg Balance Scale Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of TEAEs, Related TEAEs, SAEs, and Related SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Brain Activity Reflected by Changes of Spectral Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Predose CT1812 Plasma Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self Rated Abilities for Health Practices levels
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Advised to Start AIT Who Elected SCIT or SLIT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Who Initiated SCIT or SLIT and Completed 5 Years of Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reason for Discontinuation of SCIT or SLIT More Than 6 Months Before Completion of the Recommended Course
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Interdialytic Weight Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Responders Based on Dysmenorrhea Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced Expiratory Volume in 1 Second / Forced Vital Capacity Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rerupture rate
Endpoint domain: Mortality/survival
Primary endpoint: blood loss (ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: the rate of induced abortion syndrome (%)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in the Amount of Opioid Administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in choroid area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in choroid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients losing 3 or more lines of visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients gaining 3 or more lines of visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change from baseline in visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated dose (MTD) of mebendazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure-free patients
Endpoint domain: Mortality/survival
Primary endpoint: Treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in clinical management due to FDG-PET scan results
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Early relapse rates for PET positive and PET negative patients
Endpoint domain: Mortality/survival
Primary endpoint: Safety and tolerability of GEN-004
Endpoint domain: Adverse events/effects
Primary endpoint: Diabetes Treatment satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Libre-user evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in VO2max and muscle oxygen extraction capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: appearance of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Continuous relative phase of the trunk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pulse wave velocity (PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Central Blood Pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Reflected wave index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bile bacterial contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Hemoglobin A1c (A1C) at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Potassium intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Discriminatory value (AUC) of US in assessing liver stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discriminatory value (AUC) of US in assessing liver fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute SAE Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Short-term Chronic SAE Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Frequency of Disabling Seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Local inflammatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in systolic wall thickening (SWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intestinal decolonization of KP-OXA-48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-sb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in WOMAC A1 Pain Subscale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline in the Mean of 12-item Zarit Caregiver Burden Interview
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change from Baseline Quality of Life on the 19-item Cornell-Brown Scale for Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline symptoms on the 12-item Neuropsychiatric Inventory Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vulvovaginal atrophy vaginal dryness severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Vulvovaginal atrophy dyspareunia severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Vaginal health index total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Correct Endotracheal Tube Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Subjects With a Vaccine Response for Anti-glycoprotein E (gE) Humoral Immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)
Endpoint domain: Adverse events/effects